Company Valuation: Nectar Lifesciences Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2020 2021 2022 2023 2024 2025
Market Cap 1 2,198 4,171 5,393 3,577 6,761 5,147
Change - 89.8% 29.3% -33.68% 89.03% -23.88%
Enterprise Value (EV) 1 9,771 12,945 13,810 10,936 12,914 10,769
Change - 32.49% 6.68% -20.81% 18.08% -16.6%
P/E 6.91x -5.69x 21.5x -14.8x 137x -4.53x
PBR 0.19x 0.39x 0.5x 0.34x 0.63x 0.54x
PEG - 0x -0x 0x -1x 0x
Capitalization / Revenue 0.09x 0.27x 0.32x 0.23x 0.4x 0.31x
EV / Revenue 0.41x 0.84x 0.83x 0.72x 0.77x 0.64x
EV / EBITDA 4.44x 11.7x 8.71x 20.3x 8.41x -41.3x
EV / EBIT 6.13x 25.9x 13.6x -211x 13.9x -12.2x
EV / FCF 7.5x 6.19x -28.1x 42.1x 13.3x -63x
FCF Yield 13.3% 16.2% -3.56% 2.37% 7.52% -1.59%
Dividend per Share 2 0.05 - - - - -
Rate of return 0.51% - - - - -
EPS 2 1.418 -3.27 1.117 -1.08 0.22 -5.07
Distribution rate 3.53% - - - - -
Net sales 1 23,664 15,433 16,689 15,237 16,846 16,704
EBITDA 1 2,201 1,102 1,586 539.5 1,536 -260.8
EBIT 1 1,593 499.9 1,016 -51.73 928.4 -884.7
Net income 1 317.9 -732.6 250.5 -241.8 49.95 -1,137
Net Debt 1 7,573 8,774 8,417 7,359 6,152 5,623
Reference price 2 9.80 18.60 24.05 15.95 30.15 22.95
Nbr of stocks (in thousands) 224,261 224,261 224,261 224,261 224,261 224,261
Announcement Date 8/14/20 8/24/21 8/24/22 8/11/23 8/14/24 8/26/25
1INR in Million2INR
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 21.53M
36.43x6.89x24.07x0.88% 50.03B
17.39x2.07x9.51x1.4% 36.6B
28.68x3.5x18.13x0.87% 12.47B
26.71x3.94x16.04x0.59% 11.77B
19x3.32x11.92x3.5% 9.04B
15.69x2.02x6.33x3.29% 7.03B
8.24x1.93x5.06x5.26% 6.79B
33.91x3.86x16.43x0.24% 6.6B
Average 23.26x 3.44x 13.43x 2% 15.59B
Weighted average by Cap. 26.32x 4.23x 16.12x 1.46%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. NECLIFE Stock
  4. Valuation Nectar Lifesciences Limited